#iPSCPotential
Exciting insights from the iPSC Potential and Applications Symposium organized by the Foundation of Medical Professional Alliance in Taiwan (#FMPAT) and LumiSTAR Biotechnology, Inc. 昱星生物科技! iPSC experts discussed the vast potential of induced pluripotent stem cells (#iPSCs) and the latest trends in regenerative medicine.
Key takeaways:
Matthew Daniels from Novo Nordisk highlighted the global investment in iPSC applications and manufacturing. Challenges remain in manufacturing, potency analysis, and mechanism of action establishment.
Shih-Chia Lin of FMPAT emphasized the importance of automation and talent training in regenerative medicine production processes.
Yu-Fen Chang of LumiSTAR showcased the use of iPSC in personalized drug screening and announced the launch of its automated production equipment partnered with Molecular Devices.
Chia-Hua Maggie Ho, D.Phil. from Amarex Clinical Research, LLC, an NSF company discussed strategies to accelerate Cell and Gene Therapy (#CGT) development, emphasizing the importance of applying for a US IND before Taiwan's FDA review to streamline and facilitate the approval process in Taiwan.
Read more about the symposium here: https://lnkd.in/gdttTgke
Stay tuned to #Globalbio for more updates on the latest advancements in biotechnology!
Exciting insights from the iPSC Potential and Applications Symposium by FMPAT and LumiSTAR
撰文GlobalBio & Investment
日期2024-04-30
![](/upload/article/_images/1713185440430.jpg)
Exciting insights from the iPSC Potential and Applications Symposium by FMPAT and LumiSTAR